Oral 4`fluorouridine provides postexposure protection against lethal Nipah virus infection

1. Problem Statement

• Pathogen Threat: Nipah virus (NiV), a BSL-4 Tier 1 priority pathogen, causes severe respiratory illness and encephalitis with case fatality rates ranging from 40% to >90%. Outbreaks occur regularly in South and Southeast Asia, with potential for person-to-person transmission and deliberate misuse.
• Lack of Countermeasures: There are currently no FDA-approved vaccines or therapeutics for NiV. While monoclonal antibodies (mAbs) like m102.4 and hu1F5 show promise, they require intravenous (IV) administration, have limited blood-brain barrier penetration, and face logistical challenges in outbreak settings.
• Therapeutic Gap: Existing oral antivirals (e.g., ribavirin, remdesivir) have shown minimal to no effectiveness in preclinical NiV models. There is an urgent need for orally bioavailable broad-spectrum antivirals that can be administered post-exposure, particularly in the early stages of disease when symptoms may not yet be apparent.

2. Methodology

The study utilized a lethal Syrian golden hamster model of NiV infection (Bangladesh strain, NiVB) to evaluate the oral antiviral 4'-fluorouridine (4'-FlU; EIDD-2749).

• In Vitro Validation: Vero 76 cell monolayers were infected with NiVB in the presence of serial dilutions of 4'-FlU (100 µM to 0.391 µM). Viral load in supernatants was measured via plaque assay to determine the 50% inhibitory concentration (IC50).
• In Vivo Experimental Design:
  • Subjects: 18 Syrian golden hamsters (3–5 weeks old).
  • Challenge: All animals received an intraperitoneal (i.p.) injection of 10,000 PFU of NiVB.
  • Groups:
    1. Early Treatment (n=6): Oral gavage of 5 mg/kg 4'-FlU daily starting immediately post-challenge (Day 0) for 10 days.
    2. Delayed Treatment (n=6): Oral gavage of 5 mg/kg 4'-FlU daily starting 3 days post-infection (DPI) for 10 days.
    3. Positive Control (n=6): No treatment.
  • Monitoring: Animals were observed for 35 days for survival, weight loss, temperature changes, and clinical signs (ruffled fur, tremors, paralysis).
  • Virological Analysis:
    • Mucosal Swabs: Oral and nasal swabs collected at 3, 5, and 7 DPI to detect viral RNA (vRNA) via RT-qPCR.
    • Tissue Analysis: Spleen, lung, and brain tissues collected at necropsy to quantify vRNA load.

3. Key Contributions

• First Demonstration of Oral Post-Exposure Efficacy: This study provides the first evidence that an oral ribonucleoside analog can completely protect against lethal NiV infection when treatment is initiated after exposure.
• Timing of Intervention: The study uniquely highlights a counter-intuitive finding where delaying treatment initiation (starting at 3 DPI) resulted in superior survival outcomes compared to immediate treatment (Day 0).
• Broad-Spectrum Potential: It reinforces the utility of 4'-FlU (EIDD-2749) as a broad-spectrum antiviral effective against diverse RNA viruses, including arenaviruses (Lassa), paramyxoviruses (NiV, RSV), and coronaviruses.

4. Results

• In Vitro Activity: 4'-FlU demonstrated potent inhibition of NiVB replication in Vero 76 cells with an IC50 of 0.228 µM.
• Survival Outcomes:
  • Untreated Control: 100% mortality. All animals succumbed between 7 and 11 DPI, exhibiting severe neurological and respiratory symptoms.
  • Early Treatment (Day 0): Partial protection. Only 2/6 animals (33%) survived to the 35-day endpoint. Four animals succumbed (one on Day 21, three on Day 23).
  • Delayed Treatment (Day 3): Complete protection. 6/6 animals (100%) survived to the 35-day endpoint with no clinical signs of disease.
• Viral Load:
  • Mucosal Compartments: Treated animals (both groups) had undetectable NiVB vRNA in nasal and oral swabs. In contrast, 4/6 control animals had detectable vRNA in oral mucosa.
  • Tissue Burden: Treated survivors showed significantly lower viral titers in the lungs compared to controls. A strong correlation was observed between survival and low viral loads across all tissues (lung, spleen, brain).
• Statistical Significance: Survival curves for the Day 3 treatment group were significantly different from the untreated control group (p = 0.007).

5. Significance and Discussion

• Clinical Implications: The ability of 4'-FlU to be administered orally makes it a superior candidate for outbreak response compared to IV monoclonal antibodies. It offers a practical solution for post-exposure prophylaxis (PEP) in resource-limited settings.
• Mechanistic Insight: The authors hypothesize that the superior efficacy of the Day 3 start time may be due to:
  1. Pharmacokinetics (PK): Inflammation and infection may alter drug absorption and metabolism; waiting until the disease process is established might optimize drug distribution.
  2. Immune Priming: Treating too early (Day 0) might suppress viral replication so effectively that it prevents the host from mounting a necessary adaptive immune response, leading to rebound infection once the drug is cleared. Delaying treatment allows for initial antigen exposure to prime immunity while the drug clears the bulk of the infection.
• Future Directions: While the hamster model is useful, the authors emphasize the need for validation in African Green Monkeys (AGM), which more accurately recapitulate human NiV disease pathology. If successful, 4'-FlU could become a cornerstone of NiV medical countermeasures, potentially used in conjunction with vaccines.

Conclusion: The study establishes 4'-FlU as a highly promising oral therapeutic for NiV, capable of providing complete post-exposure protection in a lethal animal model, particularly when treatment is initiated a few days after exposure.